The Celiac Disease Foundation (CDF) was featured in a recent article in Media Planet’s USA Today’s Digestive Health campaign, distributed within the December issue of USA Today. This campaign focuses on the future of personal health. CDF’s article, “How to Maintain a Gluten-Free Diet With Celiac Disease,” discusses the transition to a gluten-free diet and […]
Accelerating diagnosis, treatments, and a cure for celiac disease and non-celiac gluten sensitivity through research, education, and advocacy.
The Celiac Disease Foundation (CDF) works tirelessly year-round to advance research toward treatments and a cure. Access to patient data is necessary to better target treatments for those with celiac disease. In CDF’s recent article featured in the December 2017 issue of Media Planet’s Digestive Health campaign of USA Today, titled “How More Participation in […]
The Food & Drug Administration (FDA), on December 12, 2017, issued guidance to drug manufacturers to voluntarily label medications with a statement indicating that gluten-containing ingredients were not used to make the product, when such a statement is true. The Celiac Disease Foundation (CDF) has been at the forefront of the fight to clearly label […]
On November 15, 2017, Celiac Disease Foundation (CDF) Chief Executive Officer, Marilyn G. Geller, was a guest on the podcast of the Celiac Disease Program at Children’s National Health System. This podcast episode focused on the importance of participating in celiac disease research. We often hear about clinical trials and research in the news, but […]
Each year, the world’s leading experts representing every aspect of celiac disease research, education, and advocacy gather at the International Celiac Disease Symposium (ICDS). As you know, there are no approved treatments for celiac disease beyond strict adherence to the gluten-free diet. And, as you know, it is estimated that approximately 30% of all celiac […]
ImmusanT, a biotechnology company focusing on protecting patients with celiac disease against the effects of gluten, has announced that it has secured $40 million in funding to advance its drug, Nexvax2®, into a Phase II clinical trial. Nexvax2 is a therapeutic vaccine designed to stimulate immune tolerance in patients with celiac disease. Nexvax2® is the […]